The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moreno-García, M. E.
Right arrow Articles by Santos-Argumedo, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moreno-García, M. E.
Right arrow Articles by Santos-Argumedo, L.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
The Journal of Immunology, 2005, 174: 2687-2695.
Copyright © 2005 by The American Association of Immunologists

CD38 Signaling Regulates B Lymphocyte Activation via a Phospholipase C (PLC)-{gamma}2-Independent, Protein Kinase C, Phosphatidylcholine-PLC, and Phospholipase D-Dependent Signaling Cascade1

Miguel E. Moreno-García*,{dagger}, Lucia N. López-Bojórques{ddagger}, Alejandro Zentella{ddagger}, Lisa A. Humphries§, David J. Rawlings§ and Leopoldo Santos-Argumedo2,{dagger}

* Departments of Cell Biology and {dagger} Molecular Biomedicine, Centro de Investigación y Estudios Avanzados, Mexico D.F. Mexico; {ddagger} Department of Cell Biology, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico D.F., Mexico; and § Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195

The CD38 cell surface receptor is a potent activator for splenic, B lymphocytes. The molecular mechanisms regulating this response, however, remain incompletely characterized. Activation of the nonreceptor tyrosine kinase, Btk, is essential for CD38 downstream signaling function. The major Btk-dependent substrate in B cells, phospholipase C-{gamma}2 (PLC-{gamma}2), functions to generate the key secondary messengers, inositol-1,4,5 trisphosphate and diacylglycerol. Surprisingly, CD38 ligation results in no detectable increase in phosphoinositide metabolism and only a minimal increase in cytosolic calcium. We hypothesized that Btk functioned independently of PLC-{gamma}2 in the CD38 signaling pathway. Accordingly, we demonstrate that CD38 cross-linking does not result in the functional phosphorylation of PLC-{gamma}2 nor an increase in inositol-1,4,5 trisphosphate production. Furthermore, splenic B cells exhibit a normal CD38-mediated, proliferative response in the presence of the phosphoinositide-PLC inhibitor, U73122. Conversely, protein kinase C (PKC) {beta}-deficient mice, or PKC inhibitors, indicated the requirement for diacylglycerol-dependent PKC isoforms in this pathway. Loss of PKC activity blocked CD38-dependent, B cell proliferation, NF-{kappa}B activation, and subsequent expression of cyclin-D2. These results suggested that an alternate diacylglycerol-producing phospholipase must participate in CD38 signaling. Consistent with this idea, CD38 increased the enzymatic activity of the phosphatidylcholine (PC)-metabolizing enzymes, PC-PLC and phospholipase D. The PC-PLC inhibitor, D609, completely blocked CD38-dependent B cell proliferation, I{kappa}B-{alpha} degradation, and cyclin-D2 expression. Analysis of Btk mutant B cells demonstrated a partial requirement for Btk in the activation of both enzymes. Taken together, these data demonstrate that CD38 initiates a novel signaling cascade leading to Btk-, PC-PLC-, and phospholipase D-dependent, PLC-{gamma}2-independent, B lymphocyte activation.




This article has been cited by other articles:


Home page
Cancer Res.Home page
F. Spadaro, C. Ramoni, D. Mezzanzanica, S. Miotti, P. Alberti, S. Cecchetti, E. Iorio, V. Dolo, S. Canevari, and F. Podo
Phosphatidylcholine-Specific Phospholipase C Activation in Epithelial Ovarian Cancer Cells
Cancer Res., August 15, 2008; 68(16): 6541 - 6549.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
F. Malavasi, S. Deaglio, A. Funaro, E. Ferrero, A. L. Horenstein, E. Ortolan, T. Vaisitti, and S. Aydin
Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology
Physiol Rev, July 1, 2008; 88(3): 841 - 886.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. C. Rodriguez-Alba, M. E. Moreno-Garcia, C. Sandoval-Montes, V. H. Rosales-Garcia, and L. Santos-Argumedo
CD38 induces differentiation of immature transitional 2 B lymphocytes in the spleen
Blood, April 1, 2008; 111(7): 3644 - 3652.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. N. Kahner, R. T. Dorsam, S. R. Mada, S. Kim, T. J. Stalker, L. F. Brass, J. L. Daniel, D. Kitamura, and S. P. Kunapuli
Hematopoietic lineage cell specific protein 1 (HS1) is a functionally important signaling molecule in platelet activation
Blood, October 1, 2007; 110(7): 2449 - 2456.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Deaglio, T. Vaisitti, R. Billington, L. Bergui, P. Omede', A. A. Genazzani, and F. Malavasi
CD38/CD19: a lipid raft-dependent signaling complex in human B cells
Blood, June 15, 2007; 109(12): 5390 - 5398.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Deaglio, T. Vaisitti, S. Aydin, E. Ferrero, and F. Malavasi
In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia
Blood, August 15, 2006; 108(4): 1135 - 1144.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
F. E. Lund, H. Muller-Steffner, H. Romero-Ramirez, M. E. Moreno-Garcia, S. Partida-Sanchez, M. Makris, N. J. Oppenheimer, L. Santos-Argumedo, and F. Schuber
CD38 induces apoptosis of a murine pro-B leukemic cell line by a tyrosine kinase-dependent but ADP-ribosyl cyclase- and NAD glycohydrolase-independent mechanism
Int. Immunol., July 1, 2006; 18(7): 1029 - 1042.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.